Chicago Partners Investment Group LLC Raises Stake in Medtronic PLC $MDT

Chicago Partners Investment Group LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 68.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,785 shares of the medical technology company’s stock after purchasing an additional 5,591 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Medtronic were worth $1,285,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC increased its holdings in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Medtronic by 6.7% in the second quarter. Assenagon Asset Management S.A. now owns 63,810 shares of the medical technology company’s stock worth $5,562,000 after buying an additional 4,016 shares in the last quarter. Accurate Wealth Management LLC boosted its stake in Medtronic by 10.8% during the second quarter. Accurate Wealth Management LLC now owns 5,693 shares of the medical technology company’s stock valued at $509,000 after buying an additional 555 shares during the period. Finally, Pitti Group Wealth Management LLC grew its position in Medtronic by 1.6% during the second quarter. Pitti Group Wealth Management LLC now owns 9,063 shares of the medical technology company’s stock worth $790,000 after buying an additional 142 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Trading Up 1.2%

MDT stock opened at $101.45 on Friday. The company has a market capitalization of $130.06 billion, a PE ratio of 27.35, a price-to-earnings-growth ratio of 2.64 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The company’s 50 day moving average price is $99.34 and its two-hundred day moving average price is $95.14.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MDT shares. Wells Fargo & Company raised their price target on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Daiwa Capital Markets lifted their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Morgan Stanley boosted their price target on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Finally, Royal Bank Of Canada raised their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Fourteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).